The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Originally a blockbuster drug, yielding billions in income, its exclusivity period created a wave of lower-priced alternatives , significantly eroding its position . While certain firms may try to capitalize on related treatments , the present landscape